Drug metabolism considerations in patients with chronic kidney disease

Journal of Pharmacy Practice

Volumn 15, Issue 5, 2002, Pages 419-427

  Dowling, Thomas C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Cytochrome P 450; Drug metabolism; Kidney disease; Pharmacokinetics

Indexed keywords

ACICLOVIR; ALLOPURINOL; AZATHIOPRINE; AZTREONAM; BENZOIC ACID; BUDESONIDE; BUMETANIDE; CAPTOPRIL; CEFTIZOXIME; CHLORAMPHENICOL; CHLORDIAZEPOXIDE; CILASTATIN; CODEINE; CYTOCHROME P450; DOPAMINE; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ETOPOSIDE; IMIPENEM; ISONIAZID; ISOTHIOCYANIC ACID; METOCLOPRAMIDE; MORPHINE; NAPHTHALENE; PARACETAMOL; PROCAINAMIDE; REBOXETINE; SPIRONOLACTONE; THIOURACIL; UNINDEXED DRUG;

BREATH ANALYSIS; CHRONIC KIDNEY DISEASE; DOSE KIDNEY FUNCTION RELATION; DRUG ACCUMULATION; DRUG ACETYLATION; DRUG CONJUGATION; DRUG DISPOSITION; DRUG METABOLISM; DRUG MONITORING; DRUG TRANSFORMATION; ENZYME INDUCTION; GLUCURONIDATION; HUMAN; HYDRATION; HYDROLYSIS; ISOMERISM; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY METABOLISM; LIVER CLEARANCE; LIVER METABOLISM; METHYLATION; NEPHROTOXICITY; NONHUMAN; OXIDATION; PHARMACEUTICAL CARE; PHARMACOGENETICS; POLYMERIZATION; PREDICTION; REDUCTION; REVIEW; SULFATION;

EID: 0036792528     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/089719002237265     Document Type: Review

References (52)

1. US Renal Data System. USRDS 2000 Annual Data Report. Bethesda, Md: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000.
2. Anderson RJ, Melikian DM, Gambertoglio JG, et al. Prescribing medication in long-term dialysis units. Arch Intern Med. 1982;142(7):1305-1308.
3. Shih YT. Effect of insurance on prescription drug use by ESRD beneficiaries. Health Care Financ Rev. 1999;20:39-54.
4. DuBose T, Cogan M, Rector F. Acid-base disorders. In: Brenner BM, ed. Brenner & Rector's The Kidney. 5th ed. Philadelphia, Pa: WB Saunders Co; 1996:929-998.
5. Klahr S. Chronic renal failure: management. Lancet. 1991;338:423.
6. Smith DA, Abel SM, Hyland R, Jones BC. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica. 1998;28:1095.
7. Wrighton S, Stevens J. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22:1.
8. Watkins P. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am. 1992;21:311.
9. Shamida T, Yamazaki H, Himura M, Inui Y, Guengerich FP. Interindividual variations in human liver CYP enzymes involved in the oxidations of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414.
10. Mosby's Drug Consult-Top 200 Prescription Drugs 2000. Available at: Genrx.com/genrxfree/Top_200_2000/Top_200_2000.html.
11. Llerena A, Berecz R, de la Rubia A, Fernandez-Salguero P, Dorado P. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit. 2001;23(6):616-620.
12. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety. 2000;23(3):215-228.
13. Prescott LF, Freestone S, McAuslane JA. The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function. Br J Clin Pharmacol. 1993;35:20.
14. Dowling TC, Frye RF, Fraley DS, Matzke GR. Characterization of tubular functional capacity in humans using paraaminohippurate and famotidine. Kidney Int. 2001;59(1):295.
15. Vree TB, Hekster Y, Anderson PG. Contribution of the human kidney to the metabolic clearance of drugs. Ann Pharmacother. 1992;26:1421.
16. Chamberlain MJ, Stimmler L. The renal handling of insulin. J Clin Invest. 1967;46:911.
17. Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med. 1970;282:182.
18. Smith D, DeFronzo RA. Insulin resistance in uremia mediated by postbinding defects. Kidney Int. 1982;22:54.
19. Stefanovic V, Vlahovic P, Ardaillou N, Ronco P, Ardaillou R. Characterization and regulation of cell surface aminopeptidases A and N activities in human glomerular epithelial cells. Kidney Int. 1992;41:1571.
20. van Der Kleij FG, de Jong PE, Henning RH, de Zeeuw D, Navis G. Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol. 2002;13(4):1025-1033.
21. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet. 2000;39(3):185.
22. Norrby SR, Rogers JD, Ferber F, et al. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother. 1984;26(5):707-714.
23. Adams SP, Notides AC. Metabolism and irreversible binding of diethylstilbesterol in the kidney of the Syrian Golden Hamster. Biochem Pharmacol. 1986;35:2171.
24. Goldstein RS, Smith PF, Tarloff JB, Contardi L, Rush GF, Hook JB. Biochemical mechanisms of cephaloridine nephrotoxicity. Life Sci. 1988;42:1809.
25. Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol. 2001;31:55.
26. Woodland C, Ito S, Granvil CP, Wainer IW, Klein J, Koren G. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci. 2000;68:109.
27. McGurk KA, Brierly CH, Burchell B. Drug glucronidation by human renal UDP-glucuronosyltransferases. Biochemical Pharmacol. 1998;55:1005.
28. Bekersky I. Use of the isolated perfused kidney as a tool in drug disposition studies. Drug Metab Rev. 1983;14:931-960. 0
29. Vree TB, Hekster Y, Anderson PG. Contribution of the human kidney to the metabolic clearance of drugs. Ann Pharmacother. 1992;26:1421-1428.
30. Uchida N, Kurata N, Shimada K, et al. Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure rats by partial nephrectomy. Jpn J Pharmacol. 1995;68:431.
31. Patterson SE, Cohn VH. Hepatic drug metabolism in rats with experimental chronic renal failure. Biochem Pharmacol. 1984;33:711.
32. Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos. 2000;28:1317.
33. Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V. Downregulation of hepatic cytochrome P450 in 0 chronic renal failure. J Am Soc Nephrol. 2001;12:326.
34. Terao N, Shen DD. Reduced extraction of l-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther. 1985;233:277-284.
35. Coulomb F, Ducret F, Laneury JP, Fiorentini F, Poggesi I, Jannuzzo MG, Fleishaker JC, Houin G, Duchene P. Pharmacokinetics of single-dose reboxetine in volunteers with renal insuffiency. J Clin Pharmacol. 2000;40:482.
36. Gibson TP. Renal disease and drug metabolism: an overview. Am J Kidney Dis. 1986;8:7.
37. Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol Ther. 2000 May;38(5):245-53.
38. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, Hasslacher C. Single- and mutiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol. 2001;57:147-152.
39. Kevorkian JP, Michel C, Hofmann U, Jacqz-Aigrain E, Kroemer HK, Peraldi MN, Eichelbaum M, Jaillon P, Funck-Brentano C. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Clin Pharmacol Ther. 1996 May;59:583.
40. Dowling TC, Briglia AE, Hanes DS, Light PD, Hise MK, Watkins PB, Henrich WL. Cytochrome P-4503A (CYP3A)-mediated drug metabolism is reduced in ESRD patients. J Am Soc Nephrol. 2000;11:59A.
41. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther. 1992;52:471.
42. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res. 2000;6:1255.
43. Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos. 1999;27:161.
44. Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet. 1996;31:410.
45. Hassan H, Bastani B, Gellens M. Successful treatment of normeperidine neurotoxicity by hemodialysis. Am J Kidney Dis. 2000;35(1):146-149.
46. Tisdale JE, Rudis MI, Padhi ID, et al. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. J Clin Pharmacol. 1995;35:902.
47. Atkinson AJ Jr, Ruo TI, Piergies AA. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide. Angiology. 1988;39:655.
48. Stevenson WG, Weiss J. Torsades de pointes due to n-acetylprocainamide. Pacing Clin Electrophysiol. 1985;8:528.
49. Dettli L. Drug dosage in renal disease. Clin Pharmacokinet. 1976;1:126.
50. Mihindu JC, Scheld WM, Bolton ND, Spyker DA, Swabb EA, Bolton WK. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob Agents Chemother. 1983;24:252.
51. Gibson GG, Skett P. Introduction to Drug Metabolism. 2nd ed. Glasgow, UK: Chapman and Hall; 1994.
52. Flockhart DA. Cytochrome P450 Drug Interaction Table (updated 4/25/02). Available at: http://medicine.iupui.edu/flockhart/p45oref2.html